Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 4/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL6865551 | 0.79 | ADAM17 (0.56) | ADAM17MMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL6865929 | 0.75 | ADAM17 (0.53) | ADAM17MMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL6759041 | 0.74 | ADAM17 (0.55) | ADAM17MMP1MMP9MMP13 | |
| SCHEMBL7043867 | 0.73 | ADAM17 (0.53) | ADAM17MMP1MMP9MMP13MEN1 | |
| SCHEMBL6863576 | 0.72 | ADAM17 (0.56) | ADAM17MMP1MMP9MMP13 | |
| Hydroxyamine SCHEMBL6865560 | 0.71 | ADAM17 (0.39) | ADAM17MMP1MMP9MMP13POLB | |
| SCHEMBL6757111 | 0.71 | KDM4E (0.47) | ADAM17MMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL7511310 | 0.71 | MMP1 (0.50) | ADAM17MMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL7512543 | 0.70 | TAS2R14 (0.50) | ADAM17MMP1MMP9MMP13KMT2A | |
| Hydroxyamine SCHEMBL7463488 | 0.70 | S1PR5 (0.52) | ADAM17MMP1MMP9MMP13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885MMP1 2/4885MMP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.